Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15988654 | 0.89 | HSP90AA1 (0.52) | HSP90AA1GAAHSP90AB1HPGDMAPT | |
| SCHEMBL6436185 | 0.84 | MAPT (0.46) | HPGDMAPTHTTMEN1LMNA | |
| SCHEMBL1276072 | 0.83 | CYP3A4 (0.49) | HSP90AA1GAAHSP90AB1HPGDMAPT | |
| SCHEMBL14284021 | 0.82 | CYP3A4 (0.46) | HSP90AA1GAAHPGDMAPTHTT | |
| SCHEMBL14284022 | 0.82 | CYP3A4 (0.46) | GAAMEN1KMT2ATDP1CYP3A4 | |
| SCHEMBL12640663 | 0.80 | TYR (0.50) | GAAHPGDMAPTHTTKDM4E | |
| SCHEMBL18029916 | 0.79 | TYR (0.50) | GAAHPGDMAPTHTTKDM4E | |
| SCHEMBL9293587 | 0.79 | POLB (0.66) | HSP90AA1GAAHPGDMAPTHTT | |
| SCHEMBL28727085 | 0.78 | KMT2A (0.41) | HPGDMAPTHTTMEN1ALOX12 | |
| SCHEMBL2268770 | 0.78 | CYP3A4 (0.56) | GAAMAPTMEN1ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351492-B2 | Introduction of alkyl substituents to aromatic compounds | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS (IL) | 2019-07-16 | — | — | US | disclosed |
| US-20180065904-A1 | INTRODUCTION OF ALKYL SUBSTITUENTS TO AROMATIC COMPOUNDS | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2018-03-08 | — | — | US | disclosed |
| US-20180065904-A1 | INTRODUCTION OF ALKYL SUBSTITUENTS TO AROMATIC COMPOUNDS | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2018-03-08 | — | — | US | disclosed |
| WO-2016132355-A1 | INTRODUCTION OF ALKYL SUBSTITUENTS TO AROMATIC COMPOUNDS | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2016-08-25 | — | — | WO | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| WO-2008021369-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-0507448-B1 | Oxidative hair dyeing process with catalytic pretreatment | BRISTOL MYERS SQUIBB CO (US) | 1996-05-29 | — | — | EP | disclosed |
| US-5316551-A | Kit including pretreatment solution of transition metal ion complexed with 2,2*-dipyridyl or o-phenanthroline; enhances dyeing efficiency; reduces damage to hair | CLAIROL INCORPORATED (US) | 1994-05-31 | — | — | US | disclosed |
| EP-0507448-A2 | Oxidative hair dyeing process with catalytic pretreatment | Bristol-Myers Squibb Company (US) | 1992-10-07 | — | — | EP | disclosed |
| US-5100436-A | Transition metal complex of 2,2*-dipyridine or 1,10-phenanthroline deposited on hair, reduced time for coloring | CLAIROL INCORPORATED (US) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | HSP90AA1 1311/4885GAA 1031/4885HSP90AB1 1173/4885 |
| US-20180065904-A1 | INTRODUCTION OF ALKYL SUBSTITUENTS TO AROMATIC COMPOUNDS | TST, NAT1, CBS | HSP90AA1 1802/4885GAA 1858/4885HSP90AB1 1781/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | HSP90AA1 1311/4885GAA 1031/4885HSP90AB1 1173/4885 |
| US-10351492-B2 | Introduction of alkyl substituents to aromatic compounds | TST, NAT1, CBS | HSP90AA1 1802/4885GAA 1858/4885HSP90AB1 1781/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | HSP90AA1 1311/4885GAA 1031/4885HSP90AB1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.